financetom
Business
financetom
/
Business
/
Engineering company L.B. Foster's Q2 adjusted EBITDA up 51.4%, backlog rises 8.1%
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Engineering company L.B. Foster's Q2 adjusted EBITDA up 51.4%, backlog rises 8.1%
Aug 11, 2025 5:14 AM

Overview

* L.B. Foster Q2 net income rises 1.3% yr/yr to $2.8 mln

* Adjusted EBITDA for Q2 up 51.4% driven by Infrastructure segment

* Company backlog increases 8.1% yr/yr, indicating potential future growth

Outlook

* L.B. Foster expects 2025 full-year net sales between $535 mln and $555 mln

* Company anticipates 2025 adjusted EBITDA between $40 mln and $44 mln

* L.B. Foster forecasts $15 mln to $25 mln in free cash flow for 2025

* Company sees strong organic sales growth continuing in second half of 2025

Result Drivers

* PRECAST CONCRETE - Sales in Precast Concrete business unit up 36%, driving Infrastructure segment growth

* RAIL BACKLOG - Rail backlog increased 13.9% yr/yr, despite 11.2% decline in Rail sales

* EXPENSE LEVERAGE - SG&A expenses decreased, contributing to improved operating income

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 EPS $0.27

Q2 Net $2.80

Income mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the heavy machinery & vehicles peer group is "buy"

* Wall Street's median 12-month price target for L B Foster Co ( FSTR ) is $29.00, about 23.9% above its August 8 closing price of $22.08

* The stock recently traded at 12 times the next 12-month earnings vs. a P/E of 11 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
MRC Global Selected as ExxonMobil's Primary Supplier of PVF Products in North America
MRC Global Selected as ExxonMobil's Primary Supplier of PVF Products in North America
Jun 13, 2024
07:45 AM EDT, 06/13/2024 (MT Newswires) -- MRC Global ( MRC ) said Thursday its subsidiary, MRC Global US was selected by ExxonMobil ( XOM ) as the primary supplier of pipe, valves, and fitting products and services in North America. This agreement encompasses all of ExxonMobil's ( XOM ) upstream and downstream facilities across North America for maintenance, repair,...
Tesla expects to raise price of China-made cars in EU after duty increase
Tesla expects to raise price of China-made cars in EU after duty increase
Jun 13, 2024
BERLIN (Reuters) -Tesla expects to increase the price of its Model 3 because of European Union import duties on electric vehicles (EVs) made in China, the carmaker said on its website on Thursday. The message, displayed on Tesla's website for countries including Germany, France, Ireland, Belgium and Hungary, urged prospective buyers to place their orders in June. The message did...
3M Transfers $2.5 Billion in Pension Obligations to Met Tower Life Insurance
3M Transfers $2.5 Billion in Pension Obligations to Met Tower Life Insurance
Jun 13, 2024
07:46 AM EDT, 06/13/2024 (MT Newswires) -- 3M ( MMM ) said Thursday that it purchased a group annuity contract to transfer about $2.5 billion of its US pension obligations for around 23,000 retirees and beneficiaries to MetLife's ( MET ) Metropolitan Tower Life Insurance. The company said this affects about 60% of the 3M Employee Retirement Income Plan retiree...
Moderna Says its Phase 3 Trial of mRNA-1283 Meets Primary Vaccine Efficacy Endpoint Against COVID-19
Moderna Says its Phase 3 Trial of mRNA-1283 Meets Primary Vaccine Efficacy Endpoint Against COVID-19
Jun 13, 2024
07:47 AM EDT, 06/13/2024 (MT Newswires) -- Moderna ( MRNA ) said Thursday that mRNA-1283, an investigational next-generation COVID-19 vaccine, met its primary vaccine efficacy endpoint in a phase 3 trial. The study demonstrated 'non-inferior vaccine efficacy' against COVID-19 compared to Spikevax (mRNA-1273) in about 11,400 participants aged 12 years and older. The company said it observed higher efficacy in...
Copyright 2023-2026 - www.financetom.com All Rights Reserved